Protein Antioxidants in Thalassemia

Advances in Clinical Chemistry

Volumn 60, Issue , 2013, Pages 85-128

  Awadallah, Samir ^a  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

Author keywords

Albumin; Antioxidative proteins; Ceruloplasmin; Ferroxidase; Glutathione; Haptoglobin; Iron overload; Oxidative stress; Thalassemia

Indexed keywords

EID: 84875118880     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407681-5.00003-9     Document Type: Chapter

References (237)

1. Higgs D.R., Thein S.L., Woods W.G. The molecular pathology of the thalassaemias. The Thalassaemia Syndromes 2001, 133-191. Blackwell Science, Oxford, England. fourth ed. D.J. Weatherall, B. Clegg (Eds.).
2. Weatherall D.J., Clegg J.B. Inherited hemoglobin disorders: an increasing global health problem. Bull. World Health Organ. 2001, 79:704-712.
3. Angastiniotis M., Modell B. Global epidemiology of hemoglobin disorders. Ann. N. Y. Acad. Sci. 1998, 850:251-269.
4. Olivieri N.F., Muraca G.M., O'Donnell A., Premawardhena A., Fisher C., Weatherall D.J. Studies in haemoglobin E beta-thalassaemia. Br. J. Haematol. 2008, 141:388-397.
5. Vichinsky E.P., MacKlin E.A., Waye J.S., Lorey F., Olivieri N.F. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005, 116:e818-e825.
6. Harteveld C.L., Higgs D.R. α-thalassaemia. Orphanet J. Rare Dis. 2010, 5:13.
7. Chan V., Chan V.W., Tang M., Lau K., Todd D., Chan T.K. Molecular defects in Hb H hydrops fetalis. Br. J. Haematol. 1997, 96:224-228.
8. Chui D.H., Fucharoen S., Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003, 101:791-800.
9. Laosombat V., Viprakasit V., Chotsampancharoen T., et al. Clinical features and molecular analysis in Thai patients with HbH disease. Ann. Hematol. 2009, 88:1185-1192.
10. Birgens H., Ljung R. The thalassaemia syndromes. Scand. J. Clin. Lab. Invest. 2007, 67:11-26.
11. Thein S.L. Genetic insights into the clinical diversity of β-thalassaemia. Br. J. Haematol. 2004, 124:264-274.
12. Galanello R., Origa R. Beta-thalassemia. Orphanet J. Rare Dis. 2010, 5:11.
13. Borgna-Pignatti C., Cappellini M.D., De Stefano P., et al. Survival and complications in thalassemia. Ann. N. Y. Acad. Sci. 2005, 1054:40-47.
14. Schrier S.L. Pathophysiology of thalassaemia. Curr. Opin. Hematol. 2002, 9:123-126.
15. Yuan J., Angelucci E., Lucarelli G., et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe β-thalassemia (Cooley's anemia). Blood 1993, 82:374-377.
16. Centis F., Tabellini L., Lucarelli G., et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β-thalassemia major. Blood 2000, 96:3624-3629.
17. Mathias L.A., Fisher T.C., Zeng L., et al. Ineffective erythropoiesis in b-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp. Hematol. 2000, 28:1343-1353.
18. Weatherall D.J. Introduction to the problem of hemoglobin EB thalassemia. J. Pediatr. Hematol. Oncol. 2000, 22:551.
19. Rees D.C., Styles L., Vichinsky E.P., Clegg J.B., Weatherall D.J. The hemoglobin E syndromes. Ann. N. Y. Acad. Sci. 1998, 850:334-343.
20. Fucharoen S., Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr. Opin. Hematol. 2000, 7:106-112.
21. Vichinsky E. Hemoglobin E syndromes. Hematology Am. Soc. Hematol. Educ. Program. 2007, 1:79-83.
22. Siah C.W., Ombiga J., Adams L.A., et al. Normal iron metabolism and the physiopathology of iron overload disorders. Clin. Biochem. Rev. 2006, 27:5-16.
23. McKie A.T., Latunde-Dada G.O., Miret S., et al. Molecular evidence for the role of a ferric reductase in iron transport. Biochem. Soc. Trans. 2002, 30:722-724.
24. Krishnamurthy P., Xie T., Schuetz J.D. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol. Ther. 2007, 114:345-358.
25. Sargent P.J., Farnaud S., Evans R.W. Structure/function overview of proteins involved in iron storage and transport. Curr. Med. Chem. 2005, 12:2683-2693.
26. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
27. Gitlin J.D. Aceruloplasminemia. Pediatr. Res. 1998, 44:271-276.
28. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
29. Schaer D.J., Schaer C.A., Buehler P.W., et al. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 2006, 107:373-380.
30. Hvidberg V., Maniecki M.B., Jacobsen C., Hojrup P., Moller H.J., Moestrup S.K. Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005, 106:2572-2579.
31. Sarkar J., Seshadri V., Tripoulas N.A., Ketterer M.E., Fox P.L. Role of ceruloplasmin in macrophage iron efflux during hypoxia. J. Biol. Chem. 2003, 278:44018-44024.
32. De Domenico I., Ward D.M., di Patti M.C., et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J. 2007, 26:2823-2831.
33. Knutson M., Wessling-Resnick M. Iron metabolism in the reticuloendothelial system. Crit. Rev. Biochem. Mol. Biol. 2003, 38:61-88.
34. Munoz M., Garci{dotless}a-Erce J.A., Remacha A.F. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J. Clin. Pathol. 2011, 64:281-286.
35. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001, 276:7806-7810.
36. Nicolas G., Bennoun M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:4596-4601.
37. Ganz T., Nemeth E. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 2011, 62:347-360.
38. Ramey G., Deschemin J.C., Durel B., et al. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica 2010, 95:501-504.
39. Hershko C., Konijn A.M., Link G. Iron chelators for thalassaemia. Br. J. Haematol. 1998, 101:399-406.
40. Ozment C.P., Turi J.L. Iron overload following red blood cell transfusion and its impact on disease severity. Biochim. Biophys. Acta 2009, 1790:694-701.
41. Rivella S., Rachmilewitz E. Future alternative therapies for β-thalassemia. Expert Rev. Hematol. 2009, 2:685.
42. Cappellini M.D., Pattoneri P. Oral iron chelators. Annu. Rev. Med. 2009, 60:25-38.
43. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102:783-788.
44. Nicolas G., Chauvet C., Viatte L., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 2002, 110:1037-1044.
45. Lee P.L., Beutler E. Regulation of hepcidin and iron-overload disease. Annu. Rev. Pathol. 2009, 4:489-515.
46. Kattamis A., Papassotiriou I., Palaiologou D., et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006, 91:809-812.
47. Origa R., Galanello R., Ganz T., et al. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 2007, 92:583-588.
48. Gardenghi S., Marongiu M.F., Ramos P., et al. Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and upregulation of ferroportin. Blood 2007, 109:5027-5035.
49. Weizer-Stern O., Adamsky K., Amariglio N., et al. mRNA expression of iron regulatory genes in β-thalassemia intermedia and β-thalassemia major mouse models. Am. J. Hematol. 2006, 81:479-483.
50. Nemeth E., Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006, 91:727-732.
51. Babitt J.L., Huang F.W., Wrighting D.M., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 2006, 38:531-539.
52. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 2007, 13:1096-1101.
53. Weizer-Stern O., Adamsky K., Amariglio N., et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br. J. Haematol. 2006, 135:129-138.
54. Langlois M.R., Martin M.-E., Boelaert J.R., et al. The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin. Chem. 2000, 46:1619-1625.
55. Buehler P.W., Abraham B., Vallelian F., et al. Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood 2009, 113:2578-2586.
56. Herz J., Strickland D.K. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 2001, 108:779-784.
57. Delanghe J.R., Langlois M.R. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin. Chim. Acta 2001, 312:13-23.
58. Bunn H.F., Jandl J.H. Exchange of heme among hemoglobins and between hemoglobin and albumin. J. Biol. Chem. 1968, 243:465-475.
59. Kakhlon O., Cabantchik Z.I. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic. Biol. Med. 2002, 33:1037-1046.
60. Breuer W., Hershko C., Cabantchik Z.I. The importance of nontransferrin bound iron in disorders of iron metabolism. Transfus. Sci. 2000, 23:185-192.
61. Cabantchik Z.I., Breuer W., Zanninelli G., Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 2005, 18:277-287.
62. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003, 102:2670-2677.
63. Randell E.W., Parkes J.G., Olivieri N.F., Templeton D.M. Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J. Biol. Chem. 1994, 269:16046-16053.
64. Breuer W., Ghoti H., Shattat A., et al. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients. Am. J. Hematol. 2012, 87:55-61.
65. May P.M., Linder P.W., Williams D.R. Computer-simulation of metal-ion equilibria in biofluids-models for low-molecular-weight complex distribution of calcium (II), magnesium(II), manganese(II), iron(III), copper (II), zinc(II) and lead(II) ions in human-blood plasma. J. Chem. Soc. Dalton Trans. 1977, 6:588-595.
66. Grootveld M., Bell J.D., Halliwell B., Aruoma O.I., Bomford A., Sadler P.J. Nontransferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis: characterization by high-performance liquid-chromatography and nuclear magnetic-resonance spectroscopy. J. Biol. Chem. 1989, 15:4417-4422.
67. Hider R.C. Nature of nontransferrin-bound iron. Eur. J. Clin. Invest. 2002, 32:50-54.
68. Silva A.M.N., Hider R.C. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. Biochim. Biophys. Acta 2009, 1794:1449-1458.
69. Evans R.W., Rafique R., Zarea A., et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem. 2008, 13:57-74.
70. Taher A., Musallam K.M., Rassi F., et al. Levels of nontransferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br. J. Haematol. 2009, 146:569-572.
71. Evans P., Kayyali R., Hider R.C., Eccleston J., Porter J.B. Mechanisms for the shuttling of plasma non-transferrin bound iron (NTBI) onto deferoxamine by deferiprone. Transl. Res. 2010, 156:55-67.
72. Walter P.B., Fung E.B., Killilea D.W., et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br. J. Haematol. 2006, 135:254-263.
73. Cighetti G., Duca L., Bortone L., et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur. J. Clin. Invest. 2002, 32(Suppl. 1):55-60.
74. Piga A., Longo F., Duca L., et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am. J. Hematol. 2009, 84:29-33.
75. Meerang M., Nair J., Sirankapracha P., et al. Increased urinary 1, N6-ethenodeoxyadenosine and 3, N4-ethenodeoxycytidine excretion in thalassemia patients: markers for lipid peroxidation-induced DNA damage. Free Radic. Biol. Med. 2008, 44:1863-1868.
76. Luechapudiporn R., Morales N.P., Fucharoen S., Chantharaksri U. The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in beta-thalassemia/Hb E. Clin. Chem. Lab. Med. 2006, 44:574-581.
77. De Luca C., Filosa A., Grandinetti M., Maggio F., Lamba M., Passi S. Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. Free Radic. Res. 1999, 30:453-462.
78. Brunori M., Falcioni G., Fioretti E., Giardina B., Rotilio G. Formation of superoxide in the autoxidation of the isolated α and β chains of human hemoglobin and its involvement in hemichrome precipitation. Eur. J. Biochem. 1975, 53:99-104.
79. Joshi W., Leb L., Piotrowski J., Fortier N., Snyder L.M. Increased sensitivity of isolated alpha subunits of normal human hemoglobin to oxidative damage and crosslinkage with spectrin. J. Lab. Clin. Med. 1983, 102:46-52.
80. Scott M.D., Rouyer-Fessard P., Lubin B.H., Beuzard Y. Entrapment of purified α-hemoglobin chains in normal erythrocytes: a model for β-thalassemia. J. Biol. Chem. 1990, 265:17953-17959.
81. Zerez C.R., Hseih J.W., Tanaka K.R. Inhibition of red blood cell enzymes by hemin: a mechanism for hemolysis in hemoglobinopathies. Trans. Assoc. Am. Physicians 1988, 100:329-338.
82. Scott M.D., Repka T., Hebbel R.P., van den Berg J.J.M., Wagner T.C., Lubin B.H. Membrane deposition of heme and non-heme iron in model thalassemic erythrocytes. Blood 1991, 78(Suppl. 1):771.
83. Scott M.D., Wagner T.C., Lubin B.H., Eaton J.W. 'Loose' iron: an important element in the pathogenesis of damage within β thalassemic erythrocytes. Blood 1991, 78(Suppl. 1):772.
84. Pootrakul P., Sirankapracha P., Hemsorach S., et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. Blood 2000, 96:2606-2612.
85. Scott M.D., van den Berg J.J.M., Repka T., et al. Effect of excess α-hemoglobin chains on cellular and membrane oxidation in model β-thalassemic erythrocytes. J. Clin. Invest. 1993, 91:1706-1712.
86. Scott M.D. H2O2 injury in β thalassemic erythrocytes: protective role of catalase and the prooxidant effects of GSH. Free Radic. Biol. Med. 2006, 40:1264-1272.
87. Vatanavicharn S., Anuwatanakulchai M., Yenchitsomanus P., Siddhikol C. Relationship of serum vitamin E, erythrocyte nonheme iron, and malonyldialdehyde (lipid membrane peroxidation product) in thalassemia. Birth Defects Orig. Artic. Ser. 1987, 23:207-211.
88. Tesoriere L., D'Arpa D., Butera D., et al. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radic. Res. 2001, 34:529-540.
89. Meral A., Tuncel P., Sürmen-Gür E., Ozbek R., Oztürk E., Günay U. Lipid peroxidation and antioxidant status in beta-thalassemia. Pediatr. Hematol. Oncol. 2000, 17:687-693.
90. Lang K.S., Roll B., Myssina S., et al. Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. Cell. Physiol. Biochem. 2002, 12:365-372.
91. Maria C., Leonardo R., Pietro R., Mario V., Isabella V., Diana T. Erythrocytes anion transport and oxidative change in beta-thalassaemias. Cell Biol. Int. 2010, 34:655-662.
92. Meerang M., Nair J., Sirankapracha P., et al. Accumulation of lipid peroxidation-derived DNA lesions in iron-overloaded thalassemic mouse livers: comparison with levels in the lymphocytes of thalassemia patients. Int. J. Cancer 2009, 125:759-766.
93. Kattamis C., Lazaropoulou C., Delaporta P., Apostolakou F., Kattamis A., Papassotiriou I. Disturbances of biomarkers of iron and oxidant-antioxidant homeostasis in patients with beta-thalassemia intermedia. Pediatr. Endocrinol. Rev. 2011, 8(Suppl. 2):256-262.
94. Carpino A., Tarantino P., Rago V., De Sanctis V., Siciliano L. Antioxidant capacity in seminal plasma of transfusion-dependent beta-thalassemic patients. Exp. Clin. Endocrinol. Diabetes 2004, 112:131-134.
95. Livrea M.A., Tesoriere L., Maggio A., D'Arpa D., Pintaudi A.M., Pedone E. Oxidative modification of low-density lipoprotein and atherogenetic risk in beta-thalassemia. Blood 1998, 92:3936-3942.
96. Tesoriere L., D'Arpa D., Maggio A., Giaccone V., Pedone E., Livrea M.A. Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia. Atherosclerosis 1998, 137:429-435.
97. Livrea M.A., Tesoriere L., Pintaudi A.M., et al. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996, 88:3608-3614.
98. Matayatsuk C., Lee C.Y., Kalpravidh R.W., et al. Elevated F2-isoprostanes in thalassemic patients. Free Radic. Biol. Med. 2007, 43:1649-1655.
99. Amer J., Dana M., Fibach E. The antioxidant effect of erythropoietin on thalassemic blood cells. Anemia 2010, 2010:978710.
100. de Franceschi L., Turrini F., Honczarenko M., et al. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica 2004, 89:1287-1298.
101. Amer J., Goldfarb A., Rachmilewitz E.A., Fibach E. Fermented papaya preparation as redox regulator in blood cells of beta-thalassemic mice and patients. Phytother. Res. 2008, 22:820-828.
102. Fibach E., Tan E.S., Jamuar S., Ng I., Amer J., Rachmilewitz E.A. Amelioration of oxidative stress in red blood cells from patients with beta-thalassemia major and intermedia and E-beta-thalassemia following administration of a fermented papaya preparation. Phytother. Res. 2010, 24:1334-1338.
103. Borenstain-Ben Yashar V., Barenholz Y., Hy-Am E., Rachmilewitz E.A., Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am. J. Hematol. 1993, 44:63-65.
104. Kean L.S., Brown L.E., Nichols J.W., Mohandas N., Archer D.R., Hsu L.L. Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. Exp. Hematol. 2002, 30:394-402.
105. Cappellini M.D., Tavazzi D., Duca L., et al. Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in beta-thalassaemia intermedia. Br. J. Haematol. 1999, 104:504-512.
106. Mannu F., Arese P., Cappellini M.D., et al. Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-thalassemia intermedia erythrocytes. Blood 1995, 86:2014-2020.
107. Matayatsuk C., Poljak A., Bustamante S., et al. Quantitative determination of ortho- and meta-tyrosine as biomarkers of protein oxidative damage in beta-thalassemia. Redox Rep. 2007, 12:219-228.
108. Awadallah S.M., Atoum M.F., Nimer N.A., Saleh S.A. Ischemia modified albumin: an oxidative stress marker in β-thalassemia major. Clin. Chim. Acta 2012, 413:907-910.
109. Yuan J., Angelucci E., Lucarelli G., et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood 1993, 82:374-377.
110. Kohen R., Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 2002, 30:620-650.
111. Abdalla M.Y., Fawzi M., Al-Maloul S.R., El-Banna N., Tayyem R.F., Ahmad I.M. Increased oxidative stress and iron overload in Jordanian β-thalassemic children. Hemoglobin 2011, 35:67-79.
112. Kalpravidh R.W., Siritanaratkul N., Insain P., et al. Improvement in oxidative stress and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids. Clin. Biochem. 2010, 43:424-429.
113. Chiou S.S., Chang T.T., Tsai S.P., et al. Lipid peroxidation and antioxidative status in beta-thalassemia major patients with or without hepatitis C virus infection. Clin. Chem. Lab. Med. 2006, 44:1226-1233.
114. Kalpravidh R.W., Wichit A., Siritanaratkul N., Fucharoen S. Effect of coenzyme Q10 as an antioxidant in beta-thalassemia/Hb E patients. Biofactors 2005, 25:225-234.
115. Naithani R., Chandra J., Bhattacharjee J., Verma P., Narayan S. Peroxidative stress and antioxidant enzymes in children with beta-thalassemia major. Pediatr. Blood Cancer 2006, 46:780-785.
116. Das N., Das Chowdhury T., Chattopadhyay A., Datta A.G. Attenuation of oxidative stress-induced changes in thalassemic erythrocytes by vitamin E. Pol. J. Pharmacol. 2004, 56:85-96.
117. Kassab-Chekir A., Laradi S., Ferchichi S., et al. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin. Chim. Acta 2003, 338:79-86.
118. Chakraborty D., Bhattacharyya M. Antioxidant defense status of red blood cells of patients with beta-thalassemia and Ebeta-thalassemia. Clin. Chim. Acta 2001, 305:123-129.
119. Gerli G.C., Mongiat R., Sandri M.T., et al. Antioxidant system and serum trace elements in alpha-thalassaemia and Hb Lepore trait. Eur. J. Haematol. 1987, 39:23-27.
120. Prasartkaew S., Bunyaratvej A., Fucharoen S., Wasi P. Comparison of erythrocyte antioxidative enzyme activities between two types of haemoglobin H disease. J. Clin. Pathol. 1986, 39:1299-1303.
121. Yenchitsomanus P., Wasi P. Increased erythrocyte superoxide dismutase activities in beta 0-thalassaemia/haemoglobin E and in haemoglobin H diseases. J. Clin. Pathol. 1983, 36:329-333.
122. Gerli G.C., Beretta L., Bianchi M., Pellegatta A., Agostoni A. Erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities in beta-thalassaemia (major and minor). Scand. J. Haematol. 1980, 25:87-92.
123. Vives Corrons J.L., Miguel-García A., Pujades M.A., et al. Increased susceptibility of microcytic red blood cells to in vitro oxidative stress. Eur. J. Haematol. 1995, 55:327-331.
124. Suthutvoravut U., Hathirat P., Sirichakwal P., Sasanakul W., Tassaneeyakul A., Feungpean B. Vitamin E status, glutathione peroxidase activity and the effect of vitamin E supplementation in children with thalassemia. J. Med. Assoc. Thai. 1993, 76(Suppl. 2):146-152.
125. Ponnazhagan S., Sarkar R. Enzymes of the pentose phosphate pathway in glutathione-regulated membrane protection in beta-thalassaemia. Eur. J. Clin. Chem. Clin. Biochem. 1992, 30:481-484.
126. Zimmerman C.P., Natta C. Glutathione peroxidase activity in whole blood of patients with sickle cell anaemia. Scand. J. Haematol. 1981, 26:177-181.
127. Beutler E., Matsumoto F., Powars D., Warner J. Increased glutathione peroxidase activity in alpha-thalassemia. Blood 1977, 50:647-655.
128. Cheng M.L., Ho H.Y., Tseng H.C., Lee C.H., Shih L.Y., Chiu D.T. Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of alpha-thalassaemia. Br. J. Haematol. 2005, 128:119-127.
129. Nagy T., Csordás M., Kósa Z., Góth L. A simple method for examination of polymorphisms of catalase exon 9: rs769217 in Hungarian microcytic anemia and beta-thalassemia patients. Arch. Biochem. Biophys. 2012, 525:201-206.
130. Kósa Z., Nagy T., Nagy E., Fazakas F., Góth L. Decreased blood catalase activity is not related to specific beta-thalassemia mutations in Hungary. Int. J. Lab. Hematol. 2012, 34:172-178.
131. Chakraborty I., Mitra S., Gachhui R., Kar M. Non-haem iron-mediated oxidative stress in haemoglobin E beta-thalassaemia. Ann. Acad. Med. Singapore 2010, 39:13-16.
132. Amer J., Atlas D., Fibach E. N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells. Biochim. Biophys. Acta 2008, 1780:249-255.
133. Amer J., Fibach E. Chronic oxidative stress reduces the respiratory burst response of neutrophils from beta-thalassaemia patients. Br. J. Haematol. 2005, 129:435-441.
134. Amer J., Fibach E. Oxidative status of platelets in normal and thalassemic blood. Thromb. Haemost. 2004, 92:1052-1059.
135. Amer J., Goldfarb A., Fibach E. Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry A 2004, 60:73-80.
136. Pfeifer W.P., Degasperi G.R., Almeida M.T., Vercesi A.E., Costa F.F., Saad S.T. Vitamin E supplementation reduces oxidative stress in beta thalassaemia intermedia. Acta Haematol. 2008, 120:225-231.
137. Dissayabutra T., Tosukhowwong P., Seksan P. The benefits of vitamin C and vitamin E in children with beta-thalassemia with high oxidative stress. J. Med. Assoc. Thai. 2005, 88(Suppl. 4):S317-S321.
138. Unchern S., Laoharuangpanya N., Phumala N., et al. The effects of vitamin E on platelet activity in beta-thalassaemia patients. Br. J. Haematol. 2003, 123:738-744.
139. Rachmilewitz E.A., Kornberg A., Acker M. Vitamin E deficiency due to increased consumption in beta-thalassemia and in Gaucher's disease. Ann. N. Y. Acad. Sci. 1982, 393:336-347.
140. Kahane I., Rachmilewitz E.A. Alterations in the red blood cell membrane and the effect of vitamin E on osmotic fragility in beta-thalassemia major. Isr. J. Med. Sci. 1976, 12:11-15.
141. Afifi A.M., Ellis L., Huntsman R.G., Said M.I. High dose ascorbic acid in the management of thalassaemia leg ulcers-a pilot study. Br. J. Dermatol. 1975, 92:339-341.
142. Gharagozloo M., Moayedi B., Zakerinia M., et al. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam. Clin. Pharmacol. 2009, 23:359-365.
143. Alidoost F., Gharagozloo M., et al. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int. Immunopharmacol. 2006, 6:1305-1310.
144. Rachmilewitz E.A., Aker M., Perry D., Dover G. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. Br. J. Haematol. 1995, 90:341-345.
145. Atasever B., Ertan N.Z., Erdem-Kuruca S., Karakas Z. In vitro effects of vitamin C and selenium on NK activity of patients with beta-thalassemia major. Pediatr. Hematol. Oncol. 2006, 23:187-197.
146. Tesoriere L., Allegra M., Butera D., Gentile C., Livrea M.A. Cytoprotective effects of the antioxidant phytochemical indicaxanthin in beta-thalassemia red blood cells. Free Radic. Res. 2006, 40:753-761.
147. Thephinlap C., Phisalaphong C., Fucharoen S., Porter J.B., Srichairatanakool S. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Med. Chem. 2009, 5:474-482.
148. Waseem F., Khemomal K.A., Sajid R. Antioxidant status in beta thalassemia major: a single-center study. Indian J. Pathol. Microbiol. 2011, 54:761-763.
149. Dhawan V., Kumar Kh.R., Marwaha R.K., Ganguly N.K. Antioxidant status in children with homozygous thalassemia. Indian Pediatr. 2005, 42:1141-1145.
150. Bartfay W.J., Bartfay E. Selenium and glutathione peroxidase with beta-thalassemia major. Nurs. Res. 2001, 50:178-183.
151. Kuppusamy U.R., Tan J.A. Chelation therapy with desferrioxamine does not normalize ferritin level but attenuates oxidative damage and improves total antioxidant level in Malaysian Chinese beta-thalassaemia major patients. West Indian Med. J. 2011, 60:3-8.
152. Grelloni F., Gabbianelli R., Santroni A.M., Falcioni G. Inactivation of glutathione peroxidase following entrapment of purified alpha or beta hemoglobin chains in human erythrocytes. Clin. Chim. Acta 1993, 217:187-192.
153. Wu G., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathione metabolism and its implications for health. J. Nutr. 2004, 134:489-492.
154. Misra H.P. Generation of superoxide free radical during the autoxidation of thiols. J. Biol. Chem. 1974, 249:2151-2155.
155. Brownlee N.R., Huttner J.J., Panganamala R.V., Cornwell D.G. Role of vitamin E in glutathione-induced oxidant stress: methemoglobin, lipid peroxidation, and hemolysis. J. Lipid Res. 1977, 18:635-644.
156. 10. J. Am. Coll. Nutr. 2001, 20:591-598.
157. Frie B., Kim B.C., Ames B.N. Ubiquinol-10 is an effective lipid soluble antioxidant at physiological concentrations. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:4879-4883.
158. Stocker R., Bowry V.W., Frie B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1646-1651.
159. Mukai K., Kikuchi S., Urano S. Stopped-flow kinetic study of regeneration reaction of tocopheroxyl radical by reduced ubiquinone-10 in solution. Biochim. Biophys. Acta 1990, 1035:77-83.
160. Kalpravidha R.W., Wichit A., Siritanaratkul N., Fucharoen S. Effect of coenzyme Q10 as an antioxidant in β-thalassemia/Hb E patients. Biofactors 2005, 25:225-234.
161. Floris G., Medda R., Padiglia A., Musci G. The physiopathological significance of caeruloplasmin. Biochem. Pharmacol. 2000, 60:1735-1741.
162. Samokyszyn V.M., Miller D., Reif D., Aust S. Inhibition of superoxide and ferritin dependent lipid peroxidation by ceruloplasmin. J. Biol. Chem. 1989, 264:21-26.
163. Gutteridge J.M. Antioxidant properties of caeruloplasmin towards iron- and copper-dependent oxygen radical formation. FEBS Lett. 1983, 157:37-40.
164. Samokyszyn V.M., Reif D.W., Miller D.M., Aust S.D. Effects of ceruloplasmin on superoxide-dependent iron release from ferritin and lipid peroxidation. Free Radic. Res. Commun. 1991, 1:153-159.
165. Young S.P., Fahmy M., Golding S. Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells. FEBS Lett. 1997, 411:93-96.
166. Attieh Z.K., Mukhopadhyay C.K., Seshadri V., Tripoulas N.A., Fox P.L. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J. Biol. Chem. 1999, 274:1116-1123.
167. Harris Z.L., Klomp L.W., Gitlin J.D. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am. J. Clin. Nutr. 1998, 67(Suppl.):972S-977S.
168. Yoshida K., Kaneko K., Miyajima H., et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J. Neurol. Sci. 2000, 175:91-95.
169. Harris Z.L., Durley A.P., Man T.K., Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:10812-10817.
170. Awadallah S.M., Nimer N.A., Atoum M.F., Saleh S.A. Association of haptoglobin phenotypes with ceruloplasmin ferroxidase activity in β-thalassemia major. Clin. Chim. Acta 2011, 412:975-979.
171. Langlois M.R., Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 1996, 42:1589-1600.
172. Muller-Eberhard U., Javid J., Liem H.H., Hanstein A., Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 1968, 32:811-815.
173. Cutillo S., Meloni T. Serum concentrations of haptoglobin and hemopexin in favism and thalassemia. Acta Haematol. 1974, 52:65-69.
174. Kalpravidh R., Weeraphan C., Srisomsap C., Siritanaratkul N., Svasti M.R.J. Proteomic analysis of plasma protein in β-thalassemia/HbE patients treated with curcumin. FASEB J. 2009, 23(Suppl.). 858.1.
175. Delanghe J.R., Langlois M.R., De Buyzere M.L. Congenital anhaptoglobinemia versus acquired hypohaptoglobinemia. Blood 1998, 91:3524.
176. Fagoonee S., Gburek J., Hirsch E., et al. Plasma protein haptoglobin modulates renal iron loading. Am. J. Pathol. 2005, 166:973-983.
177. Marro S., Barisani D., Chiabrando D., et al. Lack of haptoglobin affects iron transport across duodenum by modulating ferroportin expression. Gastroenterology 2007, 133:1261-1271.
178. Van Vlierberghe H., Langlois M., Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin. Chim. Acta 2004, 345:35-42.
179. Beutler E., Gelbart T., Lee P. Haptoglobin polymorphism and iron homeostasis. Clin. Chem. 2002, 48:2232-2235.
180. Gueye P.M., Glasser N., Ferard G., Lessinger J.M. Influence of human haptoglobin polymorphism on oxidative stress induced by free hemoglobin on red blood cells. Clin. Chem. Lab. Med. 2006, 44:542-547.
181. Balla J., Jacob H.S., Balla G., Nath K., Eaton J.W., Vercellotti G.M. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:9285-9289.
182. Hentze M., Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8175-8182.
183. Vinchi F., Gastaldi S., Silengo L., Altruda F., Tolosano E. Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload. Am. J. Pathol. 2008, 173:289-299.
184. Tolosano E., Fagoonee S., Hirsch E., et al. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 2002, 100:4201-4208.
185. Roche M., Rondeau P., Singh N.R., Tarnus E., Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008, 582:1783-1787.
186. Bourdon E., Blache D. The importance of proteins in defense against oxidation. Antioxid. Redox Signal. 2001, 3:293-311.
187. Bourdon E., Loreau N., Lagrost L., Blache D. Differential effects of cysteine and methionine residues in the antioxidant activity of human serum albumin. Free Radic. Res. 2005, 39:15-20.
188. Lim P.S., Cheng Y.M., Yang S.M. Impairments of the biological properties of serum albumin in patients on haemodialysis. Nephrology (Carlton) 2007, 12:18-24.
189. Bar-Or D., Rael L.T., Lau E.P., et al. An analog of the human albumin N-terminus (Asp-Ala-His-Lys) prevents formation of copper-induced reactive oxygen species. Biochem. Biophys. Res. Commun. 2001, 284:856-862.
190. Gutteridge J.M. Antioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritis. Biochim. Biophys. Acta 1986, 869:119-127.
191. Carballal S., Radi R., Kirk M.C., Barnes S., Freeman B.A., Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 2003, 42:9906-9914.
192. Neuzil J., Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett. 1993, 331:281-284.
193. Neuzil J., Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J. Biol. Chem. 1994, 269:16712-16719.
194. Van Campenhout A., Van Campenhout C., Lagrou A.R., Moorkens G., De Block C., Manuel-Keenoy B. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radic. Biol. Med. 2006, 40:1749-1755.
195. Bar-Or D., Curtis G., Rao N., Bampos N., Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. Eur. J. Biochem. 2001, 268:42-47.
196. Bar-Or D., Lau E., Winkler J.V. Novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J. Emerg. Med. 2000, 19:311-315.
197. Roy D., Quiles J., Gaze D.C., Collinson P., Kaski J.C., Baxter G.F. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006, 92:113-114.
198. Maxwell S.R., Thomason H., Sandler D., et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 1997, 27:484-490.
199. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:6858-6862.
200. Squadrito G.L., Cueto R., Splenser A.E., et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch. Biochem. Biophys. 2000, 376:333-337.
201. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
202. Davies K.J.A., Sevanian A., Mukkassah-Kelly S.F., Hochstein P. Uric acid-iron ion complexes: a new aspect of the antioxidant functions of uric acid. Biochem. J. 1986, 235:747-754.
203. Sevanian A., Davies K.J.A., Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am. J. Clin. Nutr. 1991, 54:1129S-1134S.
204. Shiga T., Imaizumi K. Electron spin resonance study on peroxidase and oxidase-reactions of horse radish peroxidase and methemoglobin. Arch. Biochem. Biophys. 1975, 167:469-479.
205. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
206. Stocker R., Glazer A.N., Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:5918-5922.
207. Mireles L.C., Lum M.A., Dennery P.A. Antioxidant and cytotoxic effects of bilirubin on neonatal erythrocytes. Pediatr. Res. 1999, 45:355-362.
208. Gopinathan V., Miller N.J., Milner A.D., Rice-Evans C.A. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett. 1994, 349:197-200.
209. Shekeeb Shahab M., Kumar P., Sharma N., Narang A., Prasad R. Evaluation of oxidant and antioxidant status in term neonates: a plausible protective role of bilirubin. Mol. Cell. Biochem. 2008, 317:51-59.
210. Muller L., Theile K., Bohm V. In vitro antioxidant activity of tocopherols and tocotrienols and comparison of vitamin E concentration and lipophilic antioxidant capacity in human plasma. Mol. Nutr. Food Res. 2010, 54:731-742.
211. Brigelius-Flohe R. Vitamin E: the shrew waiting to be tamed. Free Radic. Biol. Med. 2009, 46:543-554.
212. Buettner G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 1993, 300:535-543.
213. Neuzil J., Thomas S.R., Stocker R. Requirement for, promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radic. Biol. Med. 1997, 22:57-71.
214. Stoyanovsky D.A., Osipov A.N., Quinn P.J., Kagan V.E. Ubiquinone-dependent recycling of vitamin E radicals by superoxide. Arch. Biochem. Biophys. 1995, 323:343-351.
215. Traber M.G., Stevens J.F. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic. Biol. Med. 2011, 5:1000-1013.
216. Washko P.W., Wang Y., Levine M. Ascorbic acid recycling in human neutrophils. J. Biol. Chem. 1993, 268:15531-15535.
217. May J.M. Is ascorbic acid an antioxidant for the plasma membrane?. FASEB J. 1999, 13:995-1006.
218. 2-induced damage and iron homeostasis in human cells. Free Radic. Biol. Med. 2007, 43:1165-1175.
219. Herbert V., Shaw S., Jayatilleke E. Vitamin C-driven free radical generation from iron. J. Nutr. 1996, 126:1213S-1220S.
220. Santon A., Irato P., Medici V., D'Inca R., Albergoni V., Sturniolo G.C. Effect and possible role of Zn treatment in LEC rats, an animal model of Wilson's disease. Biochim. Biophys. Acta 2003, 1637:91-97.
221. Bray T.M., Bettger W.J. The physiological role of zinc as an antioxidant. Free Radic. Biol. Med. 1990, 8:281-291.
222. Kordas K., Stoltzfus R.J. New evidence of iron and zinc interplay at the enterocyte and neural tissues. J. Nutr. 2004, 134:1295-1298.
223. Formigari A., Santon A., Irato P. Efficacy of zinc treatment against iron-induced toxicity in rat hepatoma cell line H4-II-E-C3. Liver Int. 2007, 27:120-127.
224. Formigari A., Irato P., Santon A. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: biochemical and cytochemical aspects. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2007, 146:443-459.
225. Shinar E., Rachmilewitz E.A., Shifter A., Rahamim E., Saltman P. Oxidative damage to human red cells induced by copper and iron complexes in the presence of ascorbate. Biochim. Biophys. Acta 1989, 1014:66-72.
226. Bao B., Prasad A.S., Beck F.W., et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl. Res. 2008, 152:67-80.
227. Fuchs G.J., Tienboon P., Linpisarn S., et al. Nutritional factors and thalassemia major. Arch. Dis. Child. 1996, 74:224-227.
228. Shamshirsaz A., Bekheirnia1 M.R., Kamgar M. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr. Disord. 2003, 3:4.
229. Bekheiia M.R., Abdollah Shahirsaz A., Kamgar M., et al. Serum zinc and its relation to bone mineral density in beta-thalassemic adolescents. Biol. Trace Elem. Res. 2004, 97:215-224.
230. Arcasoy A., Canata D., Sinav B., et al. Serum zinc levels and zinc binding capacity in thalassemia. J. Trace Elem. Med. Biol. 2001, 15:85-87.
231. Rea F., Perrone L., Mastrobuono A., et al. Zinc levels of serum, hair and urine in homozygous beta-thalassemic subjects under hypertransfusional treatment. Acta Haematol. 1984, 71:139-142.
232. Kajanachumpol S., Tatu T., Sasanakul W., Chuansumrit A., Hathirat P. Zinc and copper status of thalassemic children. Southeast Asian J. Trop. Med. Public Health 1997, 28:877-880.
233. Aydinok Y., Coker C., Kavakli K., et al. Urinary zinc excretion and zinc status of patients with beta-thalassemia major. Biol. Trace Elem. Res. 1999, 70:165-172.
234. Uysal Z., Akar N., Kemahli S., et al. Desferrioxamine and urinary zinc excretion in beta-thalassemia major. Pediatr. Hematol. Oncol. 1993, 10:257-260.
235. Reeves M.A., Hoffmann P.R. The human selenoproteome: recent insights into functions and regulation. Cell. Mol. Life Sci. 2009, 66:2457-2478.
236. Claster S., Wood J.C., Noetzli L., et al. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am. J. Hematol. 2009, 84:344-348.
237. Atasever Belkis, Ertan Nesrin Zeynep, Erdem-Kuruca Serap In vitro effects of vitamin C and selenium on NK activity of patients with β-thalassemia major. Pediatr. Hematol. Oncol. 2006, 23:187-197.